HIV Infections Clinical Trial
Official title:
Multicenter, Open-Label, Early Acces Program of Fuzeon (Enfuvirtide T-20/Ro 29,9800, HIV-1 Fusion Inhibitor) in Combination With Free Choice Antiretroviral Regimen to Assess Serious Adverse Events, Serious AIDS-Defining Events, and Tolerability in Patient
This study will determine the safety and tolerability of Fuzeon (enfuvirtide) used together
with other treatments for HIV infection in patients with advanced HIV disease. Fuzeon is an
antiretroviral drug. Unlike other antiretrovirals, however, which work against the virus
once it is already in the cell, Fuzeon prevents the virus from getting into healthy cells.
Patients 18 years of age and older with advanced HIV-1 infection, who do not respond to
approved antiretroviral therapy, may be eligible for this study. Candidates must have a CD4
lymphocyte count less than 100 cells/mm3 and a viral load greater than 10,000 copies/mL.
They will be screened with a medical history, physical examination, and blood tests, and may
also have an electrocardiogram (ECG), chest x-ray and urine test.
Patients enrolled in the study will be re-examined and have additional blood tests before
beginning treatment with Fuzeon. They will then be taught how to self-inject the medicine
under the skin and will take two doses daily (less than 1/4 teaspoon each), 12 hours apart.
After the first treatment, participants will have follow-up visits at weeks 1, 2, 4, 8, 12,
24, 36, 48, and every 12 weeks after that, if necessary, until 12 weeks after the drug
becomes commercially available. Visits may be scheduled more often if a problem arises.
During the follow-up visits, patients will have blood drawn, and their blood pressure, pulse
rate and temperature will be checked. They will also report any drug side effects they have
experienced.
Patients may continue to take Fuzeon as long as they benefit from therapy and do not
experience severe side effects from the treatment. The drug will be provided to participants
until 12 weeks after it is sold in the United States.
Status | Completed |
Enrollment | 5 |
Est. completion date | November 2003 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: To be eligible for this trial, patients must fulfill all inclusion criteria listed below: 1. Male and female HIV-1 infected adults or adolescents (greater than or equal to 16 years of age). 2. CD4 lymphocyte count less than or equal to 100 cells/mm(3) and HIV-1 RNA viral load greater than or equal to 10,000 copies/mL while on HAART (latest available measurement must be within the last 90 days). 3. Patients must be limited by the current commercially available antiretroviral agents or agents available via Early Access or Compassionate Use Programs as per the judgment of the investigator OR patients with advanced disease and most in need defined as prior documented drug resistance or have documented evidence of greater than 6 months prior experience to each of the three classes of ARV's. 4. Patients must be able and willing to provide written informed consent (for patients less than 18 years of age, a parent or legal guardian must also sign the Informed Consent Form). 5. Women of childbearing potential must have a documented negative pregnancy test at baseline and ensure that two reliable forms of contraception are being used, including a barrier method, for the duration of the study, and for 90 days after the last dose of study medication. EXCLUSION CRITERIA: Patients meeting any of the following exclusion criteria will not be eligible for participation in this trial: 1. Female patients who are pregnant, breast-feeding, or who plan to become pregnant or breast-feed during the study. 2. Any current clinical or laboratory parameter of ACTG grade 4. Asymptomatic grade 4 abnormalities will be permitted, at the discretion of the investigator, if the potential benefit of treatment outweighs the potential risk. 3. Evidence of ongoing alcohol and/or drug or substance abuse that, in the judgment of the investigator, would result in the patient being unreliable in fulfilling the conditions of this protocol. 4. Prior non-adherence to antiretroviral treatment regimens that, in the judgment of the investigator, resulted in the patient's failing prior regimens and which would likely result in the patient being unreliable in fulfilling the conditions of this protocol. 5. Inability to self-inject Fuzeon (enfuvirtide) as indicated in the protocol, unless a reliable caregiver is willing, able, and available to provide this service on a continuous basis for the duration of the study. 6. Evidence of active, untreated opportunistic infection, intercurrent illness, drug toxicity or any other condition such that, in the judgment of the investigator, the patient would not be able to continue or take a prescribed antiretroviral regimen. |
Endpoint Classification: Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM, Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet. 1999 Jun 26;353(9171):2195-9. Erratum in: Lancet 1999 Sep 25;354(9184):1128. — View Citation
Mitsuya H, Yarchoan R, Broder S. Molecular targets for AIDS therapy. Science. 1990 Sep 28;249(4976):1533-44. Review. — View Citation
Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med. 1998 Mar 26;338(13):853-60. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05454514 -
Automated Medication Platform With Video Observation and Facial Recognition to Improve Adherence to Antiretroviral Therapy in Patients With HIV/AIDS
|
N/A | |
Completed |
NCT03760458 -
The Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less Than 12 Years of Age
|
Phase 1/Phase 2 | |
Completed |
NCT03067285 -
A Phase IV, Open-label, Randomised, Pilot Clinical Trial Designed to Evaluate the Potential Neurotoxicity of Dolutegravir/Lamivudine/Abacavir in Neurosymptomatic HIV Patients and Its Reversibility After Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide. DREAM Study
|
Phase 4 | |
Completed |
NCT03141918 -
Effect of Supplementation of Bioactive Compounds on the Energy Metabolism of People Living With HIV / AIDS
|
N/A | |
Recruiting |
NCT04579146 -
Coronary Artery Disease (CAD) in Patients HIV-infected
|
||
Completed |
NCT06212531 -
Papuan Indigenous Model of Male Circumcision
|
N/A | |
Active, not recruiting |
NCT03256422 -
Antiretroviral Treatment Taken 4 Days Per Week Versus Continuous Therapy 7/7 Days Per Week in HIV-1 Infected Patients
|
Phase 3 | |
Completed |
NCT03256435 -
Retention in PrEP Care for African American MSM in Mississippi
|
N/A | |
Completed |
NCT00517803 -
Micronutrient Supplemented Probiotic Yogurt for HIV/AIDS and Other Immunodeficiencies
|
N/A | |
Active, not recruiting |
NCT03572335 -
Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)
|
||
Completed |
NCT04165200 -
Fecal Microbiota Transplantation as a Therapeutic Strategy for Patients Infected With HIV
|
N/A | |
Recruiting |
NCT03854630 -
Hepatitis B Virus Vaccination in HIV-positive Patients and Individuals at High Risk for HIV Infection
|
Phase 4 | |
Terminated |
NCT03275571 -
HIV, Computerized Depression Therapy & Cognition
|
N/A | |
Completed |
NCT02234882 -
Study on Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01618305 -
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
|
Phase 4 | |
Recruiting |
NCT05043129 -
Safety and Immune Response of COVID-19 Vaccination in Patients With HIV Infection
|
||
Not yet recruiting |
NCT05536466 -
The Influence of Having Bariatric Surgery on the Pharmacokinetics, Safety and Efficacy of the Novel Non-nucleoside Reverse Transcriptase Inhibitor Doravirine
|
N/A | |
Recruiting |
NCT04985760 -
Evaluation of Trimer 4571 Therapeutic Vaccination in Adults Living With HIV on Suppressive Antiretroviral Therapy
|
Phase 1 | |
Completed |
NCT05916989 -
Stimulant Use and Methylation in HIV
|
||
Terminated |
NCT02116660 -
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
|
Phase 2 |